Welcome to LookChem.com Sign In|Join Free

CAS

  • or

15898-47-2

Post Buying Request

15898-47-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

15898-47-2 Usage

General Description

(Cyanomethyl)triphenylphosphonium bromide is a chemical compound that consists of a cyanomethyl group attached to a triphenylphosphonium cation, which is coordinated with a bromide anion. It is often used as a reagent in organic synthesis reactions, particularly in the preparation of cyanomethylated compounds. (CYANOMETHYL)TRIPHENYLPHOSPHONIUM BROMIDE has also been studied for its potential antimicrobial properties and has shown promise as a potential antibacterial and antifungal agent. Additionally, it has been investigated for its use in polymer chemistry and as a stabilizer for the synthesis of gold nanoparticles. Overall, (cyanomethyl)triphenylphosphonium bromide has a variety of potential applications in chemical and biological research.

Check Digit Verification of cas no

The CAS Registry Mumber 15898-47-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,8,9 and 8 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 15898-47:
(7*1)+(6*5)+(5*8)+(4*9)+(3*8)+(2*4)+(1*7)=152
152 % 10 = 2
So 15898-47-2 is a valid CAS Registry Number.

15898-47-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name cyanomethyl(triphenyl)phosphanium,bromide

1.2 Other means of identification

Product number -
Other names cyanomethyl triphenylphosphonium bromide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:15898-47-2 SDS

15898-47-2Relevant articles and documents

Isolation of the Metalated Ylides [Ph3P?C?CN]M (M=Li, Na, K): Influence of the Metal Ion on the Structure and Bonding Situation

Schwarz, Christopher,Scharf, Lennart T.,Scherpf, Thorsten,Weismann, Julia,Gessner, Viktoria H.

, p. 2793 - 2802 (2019)

The isolation and structural characterization of the cyanido-substituted metalated ylides [Ph3P?C?CN]M (1-M; M=Li, Na, K) are reported with lithium, sodium, and potassium as metal cations. In the solid-state, most different aggregates could be determined depending on the metal and additional Lewis bases. The crown-ether complexes of sodium (1-Na) and potassium (1-K) exhibited different structures, with sodium preferring coordination to the nitrogen end, whereas potassium binds in an unusual η2-coordination mode to the two central carbon atoms. The formation of the yldiide was accompanied by structural changes leading to shorter C?C and longer C?N bonds. This could be attributed to the delocalization of the free electron pairs at the carbon atom into the antibonding orbitals of the CN moiety, which was confirmed by IR spectroscopy and computational studies. Detailed density functional theory calculations show that the changes in the structure and the bonding situation were most pronounced in the lithium compounds due to the higher covalency.

Generation and Rearrangement of N,O-Dialkenylhydroxylamines for the Synthesis of 2-Aminotetrahydrofurans

Son, Jongwoo,Reidl, Tyler W.,Kim, Ki Hwan,Wink, Donald J.,Anderson, Laura L.

, p. 6597 - 6600 (2018)

A new diastereoselective route to 2-aminotetrahydrofurans has been developed from N,O-dialkenylhydroxylamines. These intermediates undergo a spontaneous C?C bond-forming [3,3]-sigmatropic rearrangement followed by a C?O bond-forming cyclization. A copper-catalyzed N-alkenylation of an N-Boc-hydroxylamine with alkenyl iodides, and a base-promoted addition of the resulting N-hydroxyenamines to an electron-deficient allene, provide modular access to these novel rearrangement precursors. The scope of this de novo synthesis of simple nucleoside analogues has been explored to reveal trends in diastereoselectivity and reactivity. In addition, a base-promoted ring-opening and Mannich reaction has been discovered to covert 2-aminotetrahydrofurans to cyclopentyl β-aminoacid derivatives or cyclopentenones.

Enantioselective Rauhut–Currier Reaction with β-Substituted Acrylamides Catalyzed by N-Heterocyclic Carbenes

Pitchumani, Venkatachalam,Breugst, Martin,Lupton, David W.

supporting information, p. 9413 - 9418 (2021/12/09)

β-Substituted acrylamides have low electrophilicity and are yet to be exploited in the enantioselective Rauhut–Currier reaction. By exploiting electron-withdrawing protection of the amide and moderate nucleophilicity N-heterocyclic carbenes, such substrates have been converted to enantioenriched quinolones. The reaction proceeds with complete diastereoselectivity, good yield, and modest enantioselectivity. Derivatizations are reported, as are computational studies, supporting decreased amide bond character with electron-withdrawing protection of the nitrogen.

METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF

-

Page/Page column 47, (2019/02/06)

The present invention relates to metallo-β-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 15898-47-2